Rectal Cancer Clinical Trial
Official title:
Comparison Between Different Approaches Applied in the Management of Early Colorectal Cancer: a Bayesian Network Meta-analysis
The diversity of definitions for the rectosigmoid junction is becoming a major obstacle to
the standardization of optimal treatment of rectal cancers. The aim of this study was to
determine the average height of the sigmoid take-off and its association with individual
factors.
Patients diagnosed with rectal and sigmoid colon cancer in our center from January 2010 to
December 2018 were retrospectively enrolled in the cancer group. The results of 200 controls
without colorectal disease were also reviewed (normal group). The distance of different
landmarks and margins of cancer from the anal verge were retrieved from computed tomography
(CT), magnetic resonance imaging (MRI), and endoscopy findings.
Method Patients All patients pathologically diagnosed with sigmoid or rectal cancer in Peking
University Third Hospital from January 2010 to December 2018 were included in our study as
the cancer group. Data regarding clinical characteristics and radiological results were
retrospectively extracted from the department's database. Patients who were found on
endoscopy to have cancer more than 20 cm from the anal verge were not included. Patients who
received emergency surgery or palliative surgery, patients with a previous history of pelvic
surgery, and patients without extractable radiological examinations were also excluded.
To evaluate the relationship between the height of the sigmoid take-off and all baseline
covariates in normal patients, the results of 200 patients without any intestinal-related
abnormalities who underwent pelvic MRI in our center from January 2019 to June 2019 were
reviewed as a normal group.
Endpoints The sigmoid take-off is the radiological sign representing the transition from
mesocolon to mesorectum. It was described as "the point that the surgeon felt there was
mobility of the colon away from the vertebral column" . The point of the sigmoid take-off was
determined by combining both the sagittal and axial planes in CT and MRI. The distance from
the anal verge was measured in sagittal planes by curvilinear distances in accordance with
the lumen of the rectum. The distances of the sacral promontory, third sacral segment, and
superior and inferior margin of cancers from the anal verge were measured in both CT and MRI
following the same standard. The distance of the anterior peritoneal reflection from the anal
verge was also measured in MRI. CT and MRI scans were reviewed originally by a junior
specialist, and the process of measurement was recorded in the form of photographs. All
photographs were then reviewed simultaneously by a senior surgeon and a senior radiologist
who were both on colorectal cancer with over fifteen years' experience and were blinded to
clinical outcomes and endoscopy results. The data were accepted if both of the senior
specialists agreed with the strategy of measurement. If either of the two senior specialists
disagreed with the measurement of a certain patient, the strategy of the measurement would be
adjusted by the junior specialist until a consensus was reached.
The heights of the superior and inferior margins of the cancers were compared with the
heights of various anatomical landmarks in order to classify cancers into different groups
according to different definitions of the rectum, and to determine how the distribution of
cancers would vary using the different definitions. Both dual classifications (sigmoid colon
cancer and rectal cancer) and triple classifications (sigmoid colon cancer, rectosigmoid
cancer, and rectal cancer) were applied. In the dual classification, only the distance of the
inferior margin of the cancer was compared with the height of certain landmarks. If the
distance of the inferior margin was below the height of the landmark, the cancer would be
classified as rectal cancer, otherwise, it would be classified as sigmoid colon cancer. In
the triple classification, a cancer would be classified as rectal cancer if the height of its
superior margin was below the height of the landmark. Rectosigmoid cancer represented cancers
straddling the landmark. As in the dual classification, cancers, whose inferior margins were
above the height of the landmark were defined as sigmoid colon cancers.
Statistical Analyses Demographic and clinicopathologic data were collected and analyzed in
both the cancer group and the normal group. Mean values with standard deviation (SD) or
median values with ranges were calculated as appropriate. The influence of factors sex and
age on the distance of the sigmoid take-off in the normal group was evaluated by
nonparametric statistics and Spearman's correlation analysis, respectively. The distances of
the sigmoid take-off as measured in the MRIs of both groups were compared using propensity
score matching method. Aside from age and sex, heights of sacral promontory, third sacral
segment, and peritoneal reflection were included in constructing the propensity score. A 1:1
matching using both optimal and greedy algorithms without replacement was adopted with a
caliper width of 0.1. Differences among results of CT, MRI, and endoscopy in the cancer group
were tested using paired T-tests. Both univariate and multivariate linear regression analyses
were carried out in both groups to explore the relationship between the height of the sigmoid
take-off and individual factors including age, sex and body habitus. Selection of variables
entering into the multivariable regression model was based on statistical significance (P<
0.100). All analyses were carried out with IBM SPSS Statistics version 22.0 for Windows. A
two-tailed P value less than 0.05 was considered statistically significant.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06380101 -
Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)
|
N/A | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Recruiting |
NCT04323722 -
Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
Active, not recruiting |
NCT01347697 -
Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer
|
N/A | |
Recruiting |
NCT04495088 -
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
|
Phase 3 | |
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Terminated |
NCT01347645 -
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03520088 -
PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS
|
N/A | |
Recruiting |
NCT05556473 -
F-Tryptophan PET/CT in Human Cancers
|
Phase 1 | |
Recruiting |
NCT04749381 -
The Role of TCM on ERAS of Rectal Cancer Patients
|
Phase 2 | |
Enrolling by invitation |
NCT05028192 -
Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
|
||
Recruiting |
NCT03283540 -
Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
|
||
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Recruiting |
NCT05914766 -
An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer
|
N/A | |
Recruiting |
NCT04852653 -
A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
|
||
Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
Terminated |
NCT02933944 -
Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
|
Phase 1 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A |